Linked Life Data

16555987

Source:http://linkedlifedata.com/resource/pubmed/id/16555987

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-3-24
pubmed:abstractText
The role of epidermal growth factor receptor (EGFR)-driven signaling in different stages of colorectal carcinogenesis, as well in the acquisition of therapy resistance, has been established. Multiple strategies have been developed for the therapeutic targeting of EGFR. Cetuximab is a chimeric monoclonal antibody selective for EGFR with efficacy alone or in combination with irinotecan in the treatment of metastatic colorectal cancer patients, who have progressed to using irinotecan-containing chemotherapy. Cetuximab is well tolerated and does not exacerbate the toxicity of concomitant chemotherapy. Based on this data, the combination of cetuximab with standard chemotherapy regimens such as irinotecan/ 5-FU/folinic acid (FA) or oxaliplatin/5-FU/FA are currently being investigated in Phase III trials for chemotherapy-naive patients with metastatic colorectal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1479-6694
pubmed:author
pubmed:issnType
Print
pubmed:volume
1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
173-81
pubmed:dateRevised
2007-5-2
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Cetuximab in the treatment of colorectal cancer.
pubmed:affiliation
Seconda Università degli Studi di Napoli, Cattedra di Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica Sperimentale F Magrassi e A Lanzara, Via S Pansini 5, 80131- Napoli, Italy. fortunato.ciardiello@unina2.it
pubmed:publicationType
Journal Article, Review